Cargando…

Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors

BACKGROUND: Life-threatening immune-related adverse events (irAEs) that require hospital admission are not uncommon in patients treated with immune checkpoint inhibitors (ICIs). The clinical and hematological parameters are attractive biomarkers as potential predictors of irAE. METHODS: This is a re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manne, Ashish, Mulekar, Madhuri S., Escobar, Daisy E., Alsayed, Alhareth, Sharma, Gaurav, Prodduturvar, Pranitha, Khushman, Moh’d, Howard, John Harrison, Gilbert, Robert, Alkharabsheh, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166288/ https://www.ncbi.nlm.nih.gov/pubmed/34104278 http://dx.doi.org/10.14740/jocmr4511

Ejemplares similares

The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma
por: Khushman, Moh’d, et al.
Publicado: (2021)

Vitamin B12 deficiency presenting as pseudo-thrombotic microangiopathy: a case report and literature review
por: Fahmawi, Yazan, et al.
Publicado: (2019)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
por: Alkharabsheh, Omar, et al.
Publicado: (2021)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
por: Shannon, Alexander H., et al.
Publicado: (2023)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
por: Jiang, Joanna, et al.
Publicado: (2022)

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma
por: Waninger, Jessica J., et al.
Publicado: (2022)

The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
por: Park, Jang Hyun, et al.
Publicado: (2022)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Ostomy Complications and Quality of Life of Ostomy Support Belt/Garment Wearers: A Web-Based Survey
por: Pittman, Joyce, et al.
Publicado: (2022)

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018)

Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies
por: Alkharabsheh, Omar, et al.
Publicado: (2019)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
por: Omar, Nabil E., et al.
Publicado: (2020)

Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?
por: Mertowska, Paulina, et al.
Publicado: (2023)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)

T lymphocyte-targeted immune checkpoint modulation in glioma
por: Kelly, William James, et al.
Publicado: (2020)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
por: Goel, Gaurav, et al.
Publicado: (2015)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Hematology and Immune-Related Disorders
por: Javinsky, Edward
Publicado: (2012)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_avq4v3omfjc3hk79gh6su3danc